Sugi Predict

Sugi Predict / Compounds / SCHEMBL1673367

SCHEMBL1673367

SCHEMBL1673367

Clc1ccc(C2CCCN2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRNB2 P17787 2/20 0.50
▸ CHRNA7 P36544 2/20 0.50
▸ CHRNA4 P43681 2/20 0.50
▸ HTR3A P46098 1/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.49
▸ MKNK1 Q9BUB5 1/20 0.47
▸ MAPKAPK2 P49137 1/20 0.45
▸ MEN1 O00255 2/20 0.44
▸ CYP2D6 P10635 2/20 0.44
▸ CYP2C19 P33261 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ POLB P06746 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ CYP2A6 P11509 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ LMNA P02545 1/20 0.43
▸ PARP1 P09874 1/20 0.43
▸ CHRM5 P08912 3/20 0.43
▸ CHRM3 P20309 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2239954 1.00 CHRNB2 (0.50) CHRNB2CHRNA7CHRNA4HTR3AL3MBTL1
SCHEMBL2300269 1.00 CHRNB2 (0.50) CHRNB2CHRNA7CHRNA4HTR3AL3MBTL1
Hydrochloric Acid SCHEMBL17437256 0.98 CHRNB2 (0.49) CHRNB2CHRNA7CHRNA4HTR3AL3MBTL1
Hydrochloric Acid SCHEMBL17437253 0.98 CHRNB2 (0.49) CHRNB2CHRNA7CHRNA4HTR3AL3MBTL1
SCHEMBL2706388 0.94 MEN1 (0.51) CHRNB2CHRNA7CHRNA4HTR3AL3MBTL1
SCHEMBL29347914 0.94 MEN1 (0.51) CHRNB2CHRNA7CHRNA4HTR3AL3MBTL1
SCHEMBL24313467 0.92 MEN1 (0.50) CHRNB2CHRNA7CHRNA4HTR3AL3MBTL1
Hydrochloric Acid SCHEMBL1764801 0.92 MEN1 (0.50) CHRNB2CHRNA7CHRNA4HTR3AL3MBTL1
SCHEMBL1945377 0.89 HTR3A (0.49) CHRNB2CHRNA7CHRNA4HTR3AL3MBTL1
SCHEMBL1945379 0.89 HTR3A (0.49) CHRNB2CHRNA7CHRNA4HTR3AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12370192-B2 Azole-fused pyridazin-3(2H)-one derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-07-29 — — US disclosed
EP-4545515-A1 BCL-2 INHIBITORS BeiGene Switzerland GmbH (CH) 2025-04-30 — — EP disclosed
WO-2025077856-A1 TRICYCLIC-CARBONYL-NITROGEN HETEROCYCLIC DERIVATIVES AND USE THEREOF Beijing Double-Crane Runchuang Technology Co., Ltd. (CN) 2025-04-17 — — WO disclosed
US-20240376104-A1 Bcl-2 Inhibitors BEIGENE LTD. (KY) 2024-11-14 — — US disclosed
EP-4031552-B1 AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES TAKEDA PHARMACEUTICALS CO (JP) 2024-11-06 — — EP disclosed
US-12077536-B2 BCL-2 inhibitors BEIGENE, LTD. (KY) 2024-09-03 — — US disclosed
CN-117683029-A Bcl-2 inhibitors 百济神州有限公司 2024-03-12 — — CN disclosed
CN-117430601-A Bcl-2 inhibitors 百济神州有限公司 2024-01-23 — — CN disclosed
EP-3280707-B1 BICYCLIC QUINAZOLINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2023-12-20 — — EP disclosed
CN-112437772-B Bcl-2 inhibitors 百济神州有限公司 2023-11-21 — — CN disclosed
US-20070049584-A1 Amino-tetrazoles analogues and methods of use ABBVIE INC. 2007-03-01 — — US disclosed
WO-2007014290-A2 FUNGICIDAL CARBOXAMIDES E. I. DU PONT DE NEMOURS AND COMPANY (US) 2007-02-01 — — WO disclosed
WO-2006124447-A2 SUBSTITUTED N-ARYLPYRROLIDINES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2006-11-23 — — WO disclosed
US-20060052374-A1 Amino-tetrazole analogues and methods of use ABBVIE INC. 2006-03-09 — — US disclosed
WO-2006015150-A1 CHIRAL PYRROLIDINE DERIVATIVES, AND METHODS FOR PREPARING COMPOUNDS THEREOF CYLENE PHARMACEUTICALS (US) 2006-02-09 — — WO disclosed
US-20060025468-A1 Chiral pyrrolidine derivatives, and methods for preparing compounds thereof CYLENE PHARMACEUTICALS 2006-02-02 — — US disclosed
EP-1165510-B1 1-ARENESULFONYL-2-ARYL-PYRROLIDINE AND PIPERIDINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS HOFFMANN LA ROCHE (CH) 2005-09-28 — — EP disclosed
EP-1165510-A1 1-ARENESULFONYL-2-ARYL-PYRROLIDINE AND PIPERIDINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2002-01-02 — — EP disclosed
US-6284785-B1 HAVING ACTIVITY AS LIGANDS OF METABOTROPIC GLUTAMATE RECEPTORS HOFFMANN- LA ROCHE INC. 2001-09-04 — — US disclosed
WO-2000058285-A1 1-ARENESULFONYL-2-ARYL-PYRROLIDINE AND PIPERIDINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2000-10-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060025468-A1 Chiral pyrrolidine derivatives, and methods for preparing compounds thereof PIN1, HPD, DHPS CHRNB2 4795/4885CHRNA7 4252/4885CHRNA4 4292/4885
US-12077536-B2 BCL-2 inhibitors BCL2, BCL2L1, BCL2L2 CHRNB2 4503/4885CHRNA7 4831/4885CHRNA4 4874/4885
US-12370192-B2 Azole-fused pyridazin-3(2H)-one derivatives GPR139, GPR119, GPR39 CHRNB2 198/4885CHRNA7 79/4885CHRNA4 243/4885
US-20240376104-A1 Bcl-2 Inhibitors BCL2, BCL2L1, BCL2L2 CHRNB2 4503/4885CHRNA7 4831/4885CHRNA4 4874/4885
US-20070049584-A1 Amino-tetrazoles analogues and methods of use P2RX7, P2RX2, P2RX5 CHRNB2 240/4885CHRNA7 174/4885CHRNA4 186/4885
US-20060052374-A1 Amino-tetrazole analogues and methods of use P2RX7, P2RX2, P2RX3 CHRNB2 218/4885CHRNA7 150/4885CHRNA4 166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.